Mesoblast Limited Sponsored ADR MESO 深 沪
等待开盘 05-21 09:30:00 美东时间
14.52
-0.030
-0.21%
华盛通- 最 高14.535
- 今 开14.35
- 成交量 20.77万股
- 最 低 14.30
- 昨 收 14.55
- 总市值 18.77亿
- 52周最高 21.50
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 9.88
- 委 比 -57.81%
- 总股本 1.29亿
- 历史最高 58.4372
- 量 比 1.14
- 振 幅 1.62%
- 历史最低 1.9406
- 每 手 1
- 风险率 2.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.
04-07 17:20
Mesoblast shares are trading lower after the company reported worse-than-expected Q4 sales results.
Mesoblast shares are trading lower after the company reported worse-than-expect...
02-28 00:45
Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.20) by 84.5 percent. This is a 99.26 percent increase over losses of $(4.20) per share from the same
02-27 15:44
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
What's Next: Mesoblast's Earnings Preview
Mesoblast (NASDAQ:MESO) is gearing up to announce its quarterly earnings on Thu...
02-26 00:02
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
Mesoblast shares fall after new Ryoncil data show high survival in severe GVHD. Company plans adult trial as analysts keep Hold rating and stock trades near key levels.
02-12 21:11
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and lower opioid use in a late-stage trial.
01-21 02:33
Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales
Mesoblast reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.
01-10 01:34
Mesoblast shares are trading higher after the company reported a year-over-year increase in December Ryoncil sales results.
Mesoblast shares are trading higher after the company reported a year-over-year...
01-09 22:13
